Isis Pharma’s diabetes drug takes longer-than-expected to work

Your Health Matters

Isis Pharmaceuticals Inc’s experimental diabetes drug took a longer-than-expected 36 weeks to reduce blood sugar levels in patients with type 2 diabetes. Isis did not disclose the effect of the drug, ISIS-PTP1B, after 26 weeks. Deutsche Bank’s Alethia Young said the data looked less robust that some commonly prescribed treatments and Isis’s own experimental glucagon receptor, ISIS-GCGR. Isis noticed that blood sugar levels kept falling even after dosing was stopped after 26 weeks, and expects the drug to lower sugar levels further over a longer duration, Young said, after speaking with the company.
Go to Source

facebookShare on Facebook
TwitterTweet
FollowFollow us
PinterestSave